David Vaudry specialises in cell biology and neuroscience. After completing his PhD in 2000, he went on to post-doc training in the laboratory of Dr Lee E. Eiden. Since 2002 he has been a researcher at INSERM, France, where, from 2008-2021 he has led the research team centred on ‘Neuropeptides, Neuronal Death and Cell Plasticity’. Since 2020 he has been Editor in Chief of the journal Neuroendocrinology. He is the author of 187 original articles, books and book chapters referenced in PubMed. He has supervised 14 PhD students and is known internationally for his work on the neurotrophic and neuroprotective effects of PACAP. Hitoshi Hashimoto received physiological chemistry training and holds a PhD from Kyoto University. In 1991, he became Assistant Professor at Osaka University, and since 2010 he has been a Professor and Chair of the Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University. He is the author of 248 original articles referenced in PubMed. He is one of the leading researchers known for research on the role of PACAP in the brain, particularly in psychiatric disorders, and has recently widened his research area to investigate neurological mechanisms using a whole-brain imaging system, block-FAce Serial microscopy Tomography (FAST) and an array of neuroscience methods.

Select Guide Rating

• I. IntroductionII. Pituitary adenylate cyclase-activating polypeptide1. Discovery and biochemical properties of PACAP (Secondary structure of PACAP, Structure of the PACAP precursor and post-translational processing)2. Cloning and phylogenetic evolution of the PACAP gene3. Development of PACAP peptidic analogs for structure-activity characterization4. Development of PACAP small molecule agonists / antagonists for therapeutic applications III. PACAP receptors5. Pharmacological, Biochemical and Signaling characterization of PACAP receptors6. Cloning and phylogenetic evolution of PACAP receptors IV. Expression of PACAP and its receptors7. Distribution of PACAP and its receptors in the central nervous system (at adulthood and during development)8. Distribution of PACAP and its receptors in peripheral organs (at adulthood and during development)9. Presence of PACAP in biological fluids10. Expression and functional implication of PACAP and its receptors in tumor cells V. Biological actions of PACAP in normal and pathological conditions A. Actions of the CNS11. Actions on the hypothalamus12. Actions of PACAP on the pineal gland and circadian rhythms13. Actions on glial cells14. Effects of PACAP on the pituitary gland15. PACAP transport across the BBB and therapeutic implication16. Neurotrophic actions during development and protective effects in acute brain injuries (stroke and spinal cord)17. Protective effect of PACAP in neurodegenerative diseases18. PACAP in migraine19. Action of PACAP in the central regulation of energy homeostasis, including food intake20. Behavioral actions of PACAP21. PACAP and stress22. PACAP and pain23. PACAP and psychiatric disorders B. Actions on peripheral organs24. Effects of PACAP on the eye25. Effects of PACAP on the thyroid gland26. Effects of PACAP on the gonads27. Effects of PACAP on the adrenal gland28. Effects of PACAP on the gastrointestinal tract29. Effects of PACAP on the liver30. Effects of PACAP on the pancreas31. Effects of PACAP on the respiratory system32. Effects of PACAP on the cardiovascular system33. Effects of PACAP on immune cells34. Effects of PACAP on bones

David Vaudry specialises in cell biology and neuroscience. After completing his PhD in 2000, he went on to post-doc training in the laboratory of Dr Lee E. Eiden. Since 2002 he has been a researcher at INSERM, France, where, from 2008-2021 he has led the research team centred on ‘Neuropeptides, Neuronal Death and Cell Plasticity’. Since 2020 he has been Editor in Chief of the journal Neuroendocrinology. He is the author of 187 original articles, books and book chapters referenced in PubMed. He has supervised 14 PhD students and is known internationally for his work on the neurotrophic and neuroprotective effects of PACAP. Hitoshi Hashimoto received physiological chemistry training and holds a PhD from Kyoto University. In 1991, he became Assistant Professor at Osaka University, and since 2010 he has been a Professor and Chair of the Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University. He is the author of 248 original articles referenced in PubMed. He is one of the leading researchers known for research on the role of PACAP in the brain, particularly in psychiatric disorders, and has recently widened his research area to investigate neurological mechanisms using a whole-brain imaging system, block-FAce Serial microscopy Tomography (FAST) and an array of neuroscience methods.

Select Guide Rating

• I. IntroductionII. Pituitary adenylate cyclase-activating polypeptide1. Discovery and biochemical properties of PACAP (Secondary structure of PACAP, Structure of the PACAP precursor and post-translational processing)2. Cloning and phylogenetic evolution of the PACAP gene3. Development of PACAP peptidic analogs for structure-activity characterization4. Development of PACAP small molecule agonists / antagonists for therapeutic applications III. PACAP receptors5. Pharmacological, Biochemical and Signaling characterization of PACAP receptors6. Cloning and phylogenetic evolution of PACAP receptors IV. Expression of PACAP and its receptors7. Distribution of PACAP and its receptors in the central nervous system (at adulthood and during development)8. Distribution of PACAP and its receptors in peripheral organs (at adulthood and during development)9. Presence of PACAP in biological fluids10. Expression and functional implication of PACAP and its receptors in tumor cells V. Biological actions of PACAP in normal and pathological conditions A. Actions of the CNS11. Actions on the hypothalamus12. Actions of PACAP on the pineal gland and circadian rhythms13. Actions on glial cells14. Effects of PACAP on the pituitary gland15. PACAP transport across the BBB and therapeutic implication16. Neurotrophic actions during development and protective effects in acute brain injuries (stroke and spinal cord)17. Protective effect of PACAP in neurodegenerative diseases18. PACAP in migraine19. Action of PACAP in the central regulation of energy homeostasis, including food intake20. Behavioral actions of PACAP21. PACAP and stress22. PACAP and pain23. PACAP and psychiatric disorders B. Actions on peripheral organs24. Effects of PACAP on the eye25. Effects of PACAP on the thyroid gland26. Effects of PACAP on the gonads27. Effects of PACAP on the adrenal gland28. Effects of PACAP on the gastrointestinal tract29. Effects of PACAP on the liver30. Effects of PACAP on the pancreas31. Effects of PACAP on the respiratory system32. Effects of PACAP on the cardiovascular system33. Effects of PACAP on immune cells34. Effects of PACAP on bones

David Vaudry specialises in cell biology and neuroscience. After completing his PhD in 2000, he went on to post-doc training in the laboratory of Dr Lee E. Eiden. Since 2002 he has been a researcher at INSERM, France, where, from 2008-2021 he has led the research team centred on ‘Neuropeptides, Neuronal Death and Cell Plasticity’. Since 2020 he has been Editor in Chief of the journal Neuroendocrinology. He is the author of 187 original articles, books and book chapters referenced in PubMed. He has supervised 14 PhD students and is known internationally for his work on the neurotrophic and neuroprotective effects of PACAP. Hitoshi Hashimoto received physiological chemistry training and holds a PhD from Kyoto University. In 1991, he became Assistant Professor at Osaka University, and since 2010 he has been a Professor and Chair of the Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University. He is the author of 248 original articles referenced in PubMed. He is one of the leading researchers known for research on the role of PACAP in the brain, particularly in psychiatric disorders, and has recently widened his research area to investigate neurological mechanisms using a whole-brain imaging system, block-FAce Serial microscopy Tomography (FAST) and an array of neuroscience methods.

Select Guide Rating

• I. IntroductionII. Pituitary adenylate cyclase-activating polypeptide1. Discovery and biochemical properties of PACAP (Secondary structure of PACAP, Structure of the PACAP precursor and post-translational processing)2. Cloning and phylogenetic evolution of the PACAP gene3. Development of PACAP peptidic analogs for structure-activity characterization4. Development of PACAP small molecule agonists / antagonists for therapeutic applications III. PACAP receptors5. Pharmacological, Biochemical and Signaling characterization of PACAP receptors6. Cloning and phylogenetic evolution of PACAP receptors IV. Expression of PACAP and its receptors7. Distribution of PACAP and its receptors in the central nervous system (at adulthood and during development)8. Distribution of PACAP and its receptors in peripheral organs (at adulthood and during development)9. Presence of PACAP in biological fluids10. Expression and functional implication of PACAP and its receptors in tumor cells V. Biological actions of PACAP in normal and pathological conditions A. Actions of the CNS11. Actions on the hypothalamus12. Actions of PACAP on the pineal gland and circadian rhythms13. Actions on glial cells14. Effects of PACAP on the pituitary gland15. PACAP transport across the BBB and therapeutic implication16. Neurotrophic actions during development and protective effects in acute brain injuries (stroke and spinal cord)17. Protective effect of PACAP in neurodegenerative diseases18. PACAP in migraine19. Action of PACAP in the central regulation of energy homeostasis, including food intake20. Behavioral actions of PACAP21. PACAP and stress22. PACAP and pain23. PACAP and psychiatric disorders B. Actions on peripheral organs24. Effects of PACAP on the eye25. Effects of PACAP on the thyroid gland26. Effects of PACAP on the gonads27. Effects of PACAP on the adrenal gland28. Effects of PACAP on the gastrointestinal tract29. Effects of PACAP on the liver30. Effects of PACAP on the pancreas31. Effects of PACAP on the respiratory system32. Effects of PACAP on the cardiovascular system33. Effects of PACAP on immune cells34. Effects of PACAP on bones